WordNet

stated explicitly or in detail; "needed a specific amount"
a medicine that has a mitigating effect on a specific disease; "quinine is a specific for malaria"
(sometimes followed by `to'
being or affecting a disease produced by a particular microorganism or condition; used also of stains or dyes used in making microscope slides; "quinine is highly specific for malaria"; "a specific remedy"; "a specific stain is one having a specific affinity for particular structural elements"
relating to or distinguishing or constituting a taxonomic species; "specific characters"
the act of tolerating something
the power or capacity of an organism to tolerate unfavorable environmental conditions
willingness to recognize and respect the beliefs or practices of others
person who makes a gift of property (同)giver, presenter, bestower, conferrer
(medicine) someone who gives blood or tissue or an organ to be used in another person (the host)
the head of an organized crime family (同)father

PrepTutorEJDIC

《名詞の前にのみ用いて》『特定の』,一定の・『明確な』,明白な・(そのものに)『特有の』,独特の《+『to』+『名』》・〈C〉(…の)特効薬《+『for』+『名』》・《複数形で》明細,細部(details)
(自分と異なる他人の意見・行動などを許す)寛大,寛容・我慢（がまん）,忍耐力 / (薬品・毒物などに対する)耐性,抗毒性 / 公差,許容誤差
寄付者,寄贈者 / (移植用の組織・器官の)提供者,献血者
《Don》ドン(Sirに当たるスペイン語で男性の洗礼名の前につける) / 〈C〉スペイン貴族(紳士) / 〈C〉(オックスフォード・ケンブリッジ両大学の)学監,指導教授 / 〈C〉《英》大学教師
〈衣服〉‘を'着る,〈帽子〉‘を'かぶる[do onの短縮形]

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 腎移植におけるHLAとABOの感作および脱感作 hla and abo sensitization and desensitization in renal transplantation
2. 移植免疫 transplantation immunobiology
3. 腎同種移植片のC4d染色および抗体媒介性拒絶反応の治療 c4d staining in renal allografts and treatment of antibody mediated rejection
4. 腎移植におけるHLAマッチングと移植片生着率 hla matching and graft survival in kidney transplantation
5. 移植腎機能不全発現後の免疫抑制治療の中止 withdrawal of immunosuppression after renal transplant failure

Mastoridis S1, Martínez-Llordella M, Sanchez-Fueyo A.
Current opinion in organ transplantation.Curr Opin Organ Transplant.2016 Feb;21(1):81-7. doi: 10.1097/MOT.0000000000000269.
PURPOSE OF REVIEW: This article describes biomarkers capable of identifying and predicting operational tolerance in solid organ transplant recipients. We outline the utility of these biomarkers in distinguishing allograft recipients in whom toxic immunosuppressive therapies might safely be minimized
PMID 26709578

A Pilot Study of Operational Tolerance with a Regulatory T Cell-Based Cell Therapy in Living Donor Liver Transplantation.

Todo S1, Yamashita K1, Goto R2, Zaitsu M2, Nagatsu A2, Oura T2, Watanabe M2, Aoyagi T2, Suzuki T2, Shimamura T3, Kamiyama T2, Sato N4, Sugita J5, Hatanaka K6, Bashuda H7, Habu S7, Demetris AJ8, Okumura K7.
Hepatology (Baltimore, Md.).Hepatology.2016 Jan 16. doi: 10.1002/hep.28459. [Epub ahead of print]
Potent immunosuppressive drugs have significantly improved early patient survival after liver transplantation. However, long-term results remain unsatisfactory due to adverse events that are largely associated with life-long immunosuppression. To solve this problem, different strategies have been un
PMID 26773713

Shipkova M1, Wieland E2.
Clinical biochemistry.Clin Biochem.2016 Jan 12. pii: S0009-9120(16)00007-2. doi: 10.1016/j.clinbiochem.2016.01.005. [Epub ahead of print]
Solid organ transplantation is inevitably associated with the activation of the immune system of the graft recipient. An advanced knowledge of the immunological mechanisms leading to acute and chronic rejection, the advent of powerful immunosuppressive drugs, and refined surgical techniques have mad
PMID 26794634